S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home

Larimar Therapeutics (LRMR) Stock Forecast, Price & News

$3.95
-0.41 (-9.40%)
(As of 09/29/2023 ET)
Compare
Today's Range
$3.87
$4.36
50-Day Range
$3.11
$4.49
52-Week Range
$2.58
$6.85
Volume
139,514 shs
Average Volume
127,800 shs
Market Capitalization
$170.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.83

Larimar Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
199.6% Upside
$11.83 Price Target
Short Interest
Healthy
1.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.81) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

392nd out of 972 stocks

Pharmaceutical Preparations Industry

164th out of 444 stocks


LRMR stock logo

About Larimar Therapeutics (NASDAQ:LRMR) Stock

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

LRMR Price History

LRMR Stock News Headlines

Larimar Therapeutics (LRMR) Receives a Buy from JMP Securities
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Larimar Therapeutics to join Russell 3000 Index
Where Larimar Therapeutics Stands With Analysts
See More Headlines
Receive LRMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LRMR Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LRMR
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.83
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+199.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-35,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.56 per share

Miscellaneous

Free Float
41,417,000
Market Cap
$170.95 million
Optionable
Not Optionable
Beta
0.50
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Carole S. Ben-Maimon M.D. (Age 64)
    CEO, Pres & Director
    Comp: $845.63k
  • Mr. Michael Celano CPA (Age 64)
    Sec. & CFO
    Comp: $562.62k
  • Mr. John Berman
    VP of Fin. & Admin.
  • Ms. Jennifer Spokes Johansson
    VP of Regulatory, Quality & Legal
  • Dr. Russell G. Clayton Sr. (Age 62)
    D.O, Chief Medical Officer
  • Dr. Gopi Shankar M.B.A. (Age 52)
    Ph.D., Chief Devel. Officer
  • Mr. Francis Michael Conway CPA
    VP & Controller













LRMR Stock - Frequently Asked Questions

Should I buy or sell Larimar Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LRMR shares.
View LRMR analyst ratings
or view top-rated stocks.

What is Larimar Therapeutics' stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month target prices for Larimar Therapeutics' shares. Their LRMR share price forecasts range from $4.50 to $17.00. On average, they predict the company's share price to reach $11.83 in the next twelve months. This suggests a possible upside of 199.6% from the stock's current price.
View analysts price targets for LRMR
or view top-rated stocks among Wall Street analysts.

How have LRMR shares performed in 2023?

Larimar Therapeutics' stock was trading at $4.13 at the beginning of 2023. Since then, LRMR stock has decreased by 4.4% and is now trading at $3.95.
View the best growth stocks for 2023 here
.

When is Larimar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our LRMR earnings forecast
.

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.02.

What is Larimar Therapeutics' stock symbol?

Larimar Therapeutics trades on the NASDAQ under the ticker symbol "LRMR."

How do I buy shares of Larimar Therapeutics?

Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Larimar Therapeutics' stock price today?

One share of LRMR stock can currently be purchased for approximately $3.95.

How much money does Larimar Therapeutics make?

Larimar Therapeutics (NASDAQ:LRMR) has a market capitalization of $170.95 million. The company earns $-35,350,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How can I contact Larimar Therapeutics?

Larimar Therapeutics' mailing address is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. The official website for the company is larimartx.com. The company can be reached via phone at (844) 511-9056 or via email at investors@larimartx.com.

This page (NASDAQ:LRMR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -